Published Jul 6, 2026, 2:58 AM ET · Updated 4 months ago · 2 sources
Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion
bloomberg
·
Original Report
INFERY
Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.